OCU400 Gene Therapy for Retinitis Pigmentosa

A Phase 3 Study of OCU400 Gene Therapy for the Treatment of Retinitis Pigmentosa ClinicalTrials.gov ID: NCT06388200 Sponsor: Ocugen Role: Sub-Investigator – Maja Kostic, MD, MMSc, PhD PI: Byron L. Lam, MD This is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded and randomized study which will enroll 150 subjects.